AMRX stock forecast, quote, news & analysis
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U... Show more
Why Amneal Pharmaceuticals (AMRX) Stock Is Up +17.2% in the Last 30 Days
Key Takeaways
- Amneal Pharmaceuticals (AMRX) shares have climbed about 17.2% over the last 30 days, rising from roughly $17.44 to about $20.44, powered by the FDA approval and immediate launch of its generic lanreotide injection.
- The approval references Ipsen's Somatuline Depot, a long-acting therapy with close to $983 million in annual U.S. sales, and received Competitive Generic Therapy (CGT) designation.
- A wave of bullish analyst actions—coverage initiations and price-target increases from Barclays, Leerink Partners, Oppenheimer, and JPMorgan—reinforced the advance and lifted sentiment.
- Over the trailing quarter the stock has gained nearly 20%, supported by a second-quarter earnings beat, raised 2026 guidance, and the completion of the Kashiv BioSciences acquisition.
Amneal Pharmaceuticals (AMRX) Company Overview and Market Position
Amneal Pharmaceuticals, headquartered in Bridgewater, New Jersey, is a diversified global biopharmaceutical company founded in 2002. The company maintains a portfolio of roughly 300 complex, specialty, and biosimilar medicines and delivers more than 160 million prescriptions each year, primarily in the United States.
Amneal operates across three business segments. Its Affordable Medicines unit spans retail generics, injectables, and biosimilars, while its Specialty segment provides branded treatments in neurology—including Parkinson's disease and migraine—and endocrinology. The AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. Investors follow the stock for its growing complex-injectables and biosimilars pipeline, its cadence of new product launches, and its transition toward higher-value, differentiated medicines.
Amneal Pharmaceuticals (AMRX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AMRX has moved from a closing price of $17.44 on September 4, 2026, to approximately $20.44, a gain of about 17.2%. The advance was not linear: the stock traded in a narrow range through most of August and early September, dipped to roughly $16.65 on September 15, and then surged sharply following its generic lanreotide approval, reaching a 52-week intraday high of $21.17 on September 21.
The trailing-quarter trend is similarly strong. From a level near $17.05 in early July 2026, the shares have risen to about $20.44, a gain of roughly 20%. This multi-month advance extends a longer uptrend that has carried AMRX well above its 52-week low of $9.49 and has placed the stock near multi-year highs.
What Drove AMRX Stock Price in the Last 30 Days
The dominant catalyst was the U.S. Food and Drug Administration's approval of Amneal's generic lanreotide injection, a biosimilar of Ipsen's Somatuline Depot used to treat acromegaly, gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. Amneal announced the approval for immediate launch, and the product received Competitive Generic Therapy designation. The reference product generated approximately $983 million in annual U.S. sales, making this a meaningful commercial opportunity in Amneal's complex-injectables portfolio. Shares rose about 12.5% in a single session following the announcement.
Supportive analyst activity amplified the move. Barclays raised its price target to $20 from $16 and maintained an Overweight rating, describing the pending approval as a "clearing event." Leerink Partners initiated coverage with an Outperform rating and later reiterated a Buy with a $23 target, while Oppenheimer initiated coverage at Outperform with a $27 target. JPMorgan reiterated an Overweight rating with a $22 target. Collectively, these actions reinforced a consensus view that Amneal's complex generics and biosimilars pipeline can sustain high single-digit sales growth.
What Drove AMRX Stock Performance Over the Last Quarter
The broader quarterly trend reflects improving fundamentals rather than a single headline. On July 30, 2026, Amneal reported second-quarter results that exceeded expectations: revenue rose 9.9% year over year to $796.2 million, and adjusted EPS of $0.30 beat the consensus estimate by roughly 33%. Management raised full-year revenue guidance to a range of $3.10–$3.20 billion and lifted adjusted EBITDA and adjusted EPS guidance.
Several strategic developments also shaped the quarter. Amneal completed its acquisition of Kashiv BioSciences in August 2026, deepening its biosimilars platform, and secured additional FDA approvals, including a ready-to-use romidepsin injection with 180 days of exclusivity and a bortezomib product. The company also advanced its Specialty franchise with positive interim Phase 4 ELEVATE PD results and the launch of CREXONT for Parkinson's disease. A manufacturing and supply collaboration for GLP-1 therapies with Metsera, now owned by Pfizer, further positioned Amneal in complex injectables and peptides. Peers such as Teva Pharmaceutical Industries (TEVA) and Neurocrine Biosciences (NBIX) provide useful comparisons across generics and branded neurology.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this featured section. These bots vary in trading strategy, timeframe, and performance metrics, giving traders a range of approaches to review alongside their own research. For those following AMRX and similar names, the page offers a practical way to observe how algorithmic strategies are currently positioned across the market.
AMRX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on Amneal's ability to execute its launch cadence. The company expects to introduce 20–30 Affordable Medicines products annually, including complex products, and a biosimilar referencing Novartis' Xolair is under review with a potential launch by the end of 2026 if approved. The FDA has also accepted abbreviated new drug applications for generic tirzepatide autoinjectors referencing Mounjaro and Zepbound.
Key risks include the loss of exclusivity on Rytary, where an authorized generic has already launched and additional generic entrants are expected, which could limit Specialty segment growth. Broader U.S. generics pricing pressure, regulatory approval delays, and slower-than-expected adoption of complex injectables and biosimilars remain meaningful offsets. Amneal's valuation has also moved above its own historical averages, raising the bar for continued execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AMRX sees its Stochastic Oscillator recovers from oversold territory
On October 20, 2026, the Stochastic Oscillator for AMRX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In 51 of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on AMRX as a result. In 71 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
AMRX moved above its 50-day moving average on September 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AMRX crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +4.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRX advanced for three days, in 245 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
AMRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for AMRX moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 33 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Moving Average Convergence Divergence Histogram (MACD) for AMRX turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 27 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for AMRX entered a downward trend on September 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. AMRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AMRX's P/B Ratio (213.044) is very high in comparison to the industry average of (11.138). P/E Ratio (40.400) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (1.947) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (1.899) is also within normal values, averaging (178.797).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry PharmaceuticalsGeneric